Featuring Jeff Flake (R-AZ), United States Senator; Dave Brat (R-VA-7), United States Congressman; Michael F. Cannon, Director of Health Policy Studies, Cato Institute; John C. Goodman, President, Goodman Institute for Public Policy Research; moderated by Peter Russo, Director of Congressional Affairs, Cato Institute.
In Lukewarming: The New Climate Science that Changes Everything, Pat Michaels and Chip Knappenberger explain the real science and spin behind the headlines and come to a provocative conclusion: global warming is not hot—it’s lukewarm. Climate change is real, it is partially man-made, but it is clearer than ever that its impact has been exaggerated—with many predictions now being rendered implausible or impossible. This new paperback edition of the book is an expanded edition of last year’s ebook-only edition of Lukewarming, and includes updates in science and policy following the accords reached at the 2015 United Nations Climate Change Conference in Paris.
The Cato Institute has released its 2015 Annual Report, which documents a dynamic year of growth and productivity. The thousands of individuals who contribute to Cato are passionate about freedom and committed to ensuring that future generations enjoy the blessings of liberty, unencumbered by an overreaching state that seeks to control their lives. This is Cato’s optimistic vision for the future, and it would be unimaginable without the Institute’s longstanding partnership with its Sponsors. We will continue our diligence and dedication to seeing this vision realized.
Should the Government Insert Itself between Dying Patients and Unproven Therapies?
Featuring J. Scott Ballenger, Partner, Latham & Watkins; Ezekiel J. Emanuel, Chair, Department of Clinical Bioethics, National Institutes of Health; and Michael F. Cannon, Director of Health Policy Studies, Cato Institute.
In Abigail Alliance for Better Access to Developmental Drugs v. Eschenbach, terminally ill patients won an impressive victory before a panel of the U.S. Court of Appeals for the D.C. Circuit. That panel ruled that when the government prevents terminally ill patients from accessing experimental drug treatments, it violates those patients’ constitutionally protected right to save their own lives. On appeal, however, an en banc opinion from the D.C. Circuit overturned the panel opinion, setting the stage for an appeal to the Supreme Court. Please join Michael F. Cannon, the Cato Institute’s director of health policy studies; Scott Ballenger, lead counsel for the Abigail Alliance; and Ezekiel Emanuel, a leading critic of the Abigail Alliance’s case as they discuss the economics, ethics, and constitutionality of allowing the state to stand between dying patients and unproven therapies.